Norgine is a European specialist pharmaceutical company founded in 1906. It describes a long-standing focus on acquiring, developing, and commercializing medicines and reports operations across major European markets. The company states it is headquartered in the Netherlands, with key sites in the UK and France.
X4 Pharmaceuticals is on track to complete enrollment of its Phase 3 4WARD trial for mavorixafor in chronic neutropenia by Q3 2026, targeting a 2028 launch. The European Commission approved XOLREMDI for WHIM syndrome, while the company cuts costs and deprioritizes WHIM commercialization.
Vir Biotechnology reported Q4 EPS of ($0.31), beating estimates by $0.23, with revenue of $64.07 million. The company announced a global strategic collaboration with Astellas for VIR-5500 and reported $781.6 million in cash and investments.
Vir Biotechnology announced a global strategic collaboration with Astellas for VIR-5500, a PSMA-targeted dual-masked T-cell engager for prostate cancer, and reported $781.6 million in cash and investments as of December 31, 2025.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07218523 |
A Study to Investigate Bowel Cleansing With PLENVU® Compared to Sodium Picosulfate in Participants Aged 1 to < 18 Years of Age in Preparation for Colonoscopy |
RECRUITING | PHASE3 |
| NCT06597903 |
A Monocentric Study to Investigate a New Low Dose Oral Gut Cleansing Solution |
COMPLETED | PHASE2 |
| NCT06593743 |
The Safety and Dose Response to Single Anal Doses of NRL001 |
COMPLETED | PHASE1 |
| NCT06593730 |
Safety and Tolerability of the Twice Daily Intra-anal Application of NRL001 Cream for 14 Days |
COMPLETED | PHASE1 |
| NCT05697211 |
ORal IrON Supplementation with Ferric Maltol in Treating Iron Deficiency and Anaemia in Patients with Heart Failure (ORION-HF) |
COMPLETED | PHASE4 |
| NCT05436054 |
A Trial to Compare Efficacy and Tolerability of Plenvu® and Picoprep® as Cleansing Agents Before Colonoscopy |
RECRUITING | PHASE4 |
| NCT05177484 |
Perioperative Iron for Colorectal Cancer (PICoC Study) |
COMPLETED | PHASE3 |
| NCT05174845 |
Real Word Evidence With 1L Polyethylene Glycol (PEG)+ Ascorbic Acid in Iberia |
COMPLETED | |
| NCT04487912 |
Dynamics and Tracer Distribution of Tilmanocept in Early Stage Breast Cancer |
WITHDRAWN | PHASE4 |
| NCT04073290 |
Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose |
RECRUITING | PHASE4 |
